Synergy of 1,25-dihydroxyvitamin D3 and Carboplatin in Growth Suppression of SKOV-3 Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2014 Aug 15

PMID 25120722

Citations 13

Authors

Zengli Zhang

Hemei Zhang

Zhiyong Hu

Ping Wang

Jianmei Wan

Bingyan Li

Affiliations

Soon will be listed here.

Abstract

1α,25-Dihydroxyvitamin D3 [1,25(OH)D] has been demonstrated to inhibit the growth of cancer cells. However, carboplatin is the most widely used chemotherapeutic agent to treat cancer. We hypothesized that vitamin D may enhance the antiproliferative effects of carboplatin, and tested this hypothesis in ovarian cancer SKOV-3 cells treated with carboplatin and 1,25(OH)D. Cell viability was determined by Cell Counting Kit-8, while cell cycle distribution, apoptosis, reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) were analyzed by flow cytometry. In these experiments, 1,25(OH)D and carboplatin each provided dose-dependent suppression of SKOV-3 growth, and synergy was demonstrated between 10 nM 1,25(OH)D and carboplatin. The proportion of cells in G/G phase was markedly reduced by the drug combination, while the proportion of cells in G/M phase was increased. Apoptosis did not increase in ovarian cancer cells treated with 10 nM 1,25(OH)D alone; however, 1,25(OH)D evidently enhanced carboplatin-induced apoptosis. Similarly, ROS production was evidently higher and MMP was lower in cells treated with the two drugs than in those treated with each drug alone. The results suggested that 1,25(OH)D suppresses SKOV-3 growth and enhances the antiproliferative effect of carboplatin. The drugs function synergistically by inducing cell cycle arrest, increasing apoptosis and ROS production, and reducing MMP.

Citing Articles

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.

Luserna di Rora A, Cerchione C, Martinelli G, Simonetti G J Hematol Oncol. 2020; 13(1):126.

PMID: 32958072 PMC: 7507691. DOI: 10.1186/s13045-020-00959-2.

Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms.

Dovnik A, Dovnik N Cells. 2020; 9(2).

PMID: 32024052 PMC: 7072673. DOI: 10.3390/cells9020335.

Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis.

Cui D, Liang T, Sun L, Meng L, Yang C, Wang L Pharm Biol. 2018; 56(1):528-534.

PMID: 30387372 PMC: 6225412. DOI: 10.1080/13880209.2018.1510974.

The role of vitamin D in ovarian cancer: epidemiology, molecular mechanism and prevention.

Guo H, Guo J, Xie W, Yuan L, Sheng X J Ovarian Res. 2018; 11(1):71.

PMID: 30157901 PMC: 6114234. DOI: 10.1186/s13048-018-0443-7.

1α,25-dihydroxyvitamin D3 Attenuates TGF-β-Induced Pro-Fibrotic Effects in Human Lung Epithelial Cells through Inhibition of Epithelial-Mesenchymal Transition.

Jiang F, Yang Y, Xue L, Li B, Zhang Z Nutrients. 2017; 9(9).

PMID: 28878195 PMC: 5622740. DOI: 10.3390/nu9090980.

References

Bookman M, Brady M, McGuire W, Harper P, Alberts D, Friedlander M . Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27(9):1419-25. PMC: 2668552. DOI: 10.1200/JCO.2008.19.1684. View

Chen W, Huang Y, Wu M, Huang T, Ho C, Pan M . Induction of apoptosis by vitamin D2, ergocalciferol, via reactive oxygen species generation, glutathione depletion, and caspase activation in human leukemia Cells. J Agric Food Chem. 2008; 56(9):2996-3005. DOI: 10.1021/jf0730744. View

Weitsman G, Ravid A, Liberman U, Koren R . Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. Ann N Y Acad Sci. 2004; 1010:437-40. DOI: 10.1196/annals.1299.079. View

Cheng T, Manorek G, Samimi G, Lin X, Berry C, Howell S . Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol. 2006; 58(3):384-95. DOI: 10.1007/s00280-005-0171-8. View

Roberts D, Schick J, Conway S, Biade S, Laub P, Stevenson J . Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer. 2005; 92(6):1149-58. PMC: 2361951. DOI: 10.1038/sj.bjc.6602447. View

Koren R, Rocker D, Kotestiano O, Liberman U, Ravid A . Synergistic anticancer activity of 1,25-dihydroxyvitamin D(3) and immune cytokines: the involvement of reactive oxygen species. J Steroid Biochem Mol Biol. 2000; 73(3-4):105-12. DOI: 10.1016/s0960-0760(00)00068-6. View

Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J . Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol. 2004; 93(3):699-701. DOI: 10.1016/j.ygyno.2004.03.023. View

Walters M . Newly identified actions of the vitamin D endocrine system. Endocr Rev. 1992; 13(4):719-64. DOI: 10.1210/edrv-13-4-719. View

Soriano A, Helfrich B, Chan D, Heasley L, Bunn Jr P, Chou T . Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 2000; 59(24):6178-84. View

10.

Agarwal R, Kaye S . Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3(7):502-16. DOI: 10.1038/nrc1123. View

11.

Evans S, Shchepotin E, Young H, Rochon J, Uskokovic M, Shchepotin I . 1,25-dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. Int J Oncol. 2000; 16(6):1249-54. DOI: 10.3892/ijo.16.6.1249. View

12.

Poulsen H, Prieme H, Loft S . Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev. 1998; 7(1):9-16. View

13.

Bao B, Ting H, Hsu J, Lee Y . Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer. 2008; 122(12):2699-706. DOI: 10.1002/ijc.23460. View

14.

Koli K, Keski-Oja J . 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000; 11(4):221-9. View

15.

Jiang F, Bao J, Li P, Nicosia S, Bai W . Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem. 2004; 279(51):53213-21. DOI: 10.1074/jbc.M410395200. View

16.

Dokoh S, Donaldson C, Marion S, Pike J, Haussler M . The ovary: a target organ for 1,25-dihydroxyvitamin D3. Endocrinology. 1983; 112(1):200-6. DOI: 10.1210/endo-112-1-200. View

17.

Marchionatti A, Picotto G, Narvaez C, Welsh J, Tolosa de Talamoni N . Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells. J Steroid Biochem Mol Biol. 2009; 113(3-5):227-32. DOI: 10.1016/j.jsbmb.2009.01.004. View

18.

Stordal B, Pavlakis N, Davey R . A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 2007; 33(8):688-703. DOI: 10.1016/j.ctrv.2007.07.013. View

19.

Saunders D, Christensen C, Lawrence W, Malviya V, Malone J, Williams J . Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms. Gynecol Oncol. 1992; 44(2):131-6. DOI: 10.1016/0090-8258(92)90028-h. View

20.

Moffatt K, Johannes W, Miller G . 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 1999; 5(3):695-703. View